Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMineralys Therapeutics prices $150M offering at $26.50/share to fund Tanabe royalty buyback
Filed June 3, 2026 · ~1 min read
Offering filing cluster
Same offering- 424B5 Jun 3, 2026 This filing EDGAR →
- 8-K Jun 3, 2026 Mineralys buys out lorundrostat royalties for $200M, secures $500M debt facility EDGAR →
Key Changes
-
high
Offering 5.7M shares at $26.50/share (below $28.85 last market price) for $150M gross proceeds; net proceeds $143.3M after underwriting discount.
The Offering verify on EDGAR → -
high
Proceeds will fund part of $200M upfront payment to repurchase royalty obligation under Tanabe license agreement.
Risk Factors verify on EDGAR → -
high
Implied post-offering market cap $2.3B ($26.50 offer price × 88.1M shares outstanding after offering).
The Offering verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (STZ 10-Q) is open in full — no account needed.
Partner
Trade MLYS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 8, 2026 · How we verify